Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTN3A1 | O00481 | 12/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2521572 | 1.00 | BTN3A1 (0.50) | BTN3A1CYP3A4CYP2C9MEN1KMT2A | |
| SCHEMBL16690101 | 1.00 | BTN3A1 (0.50) | BTN3A1CYP3A4CYP2C9MEN1KMT2A | |
| SCHEMBL2549985 | 1.00 | BTN3A1 (0.50) | BTN3A1CYP3A4CYP2C9MEN1KMT2A | |
| SCHEMBL30208193 | 1.00 | BTN3A1 (0.50) | BTN3A1CYP3A4CYP2C9MEN1KMT2A | |
| SCHEMBL16081101 | 1.00 | BTN3A1 (0.50) | BTN3A1CYP3A4CYP2C9MEN1KMT2A | |
| SCHEMBL2510991 | 1.00 | BTN3A1 (0.50) | BTN3A1CYP3A4CYP2C9MEN1KMT2A | |
| SCHEMBL2512431 | 1.00 | BTN3A1 (0.50) | BTN3A1CYP3A4CYP2C9MEN1KMT2A | |
| SCHEMBL850195 | 1.00 | BTN3A1 (0.50) | BTN3A1CYP3A4CYP2C9MEN1KMT2A | |
| SCHEMBL2510990 | 1.00 | BTN3A1 (0.50) | BTN3A1CYP3A4CYP2C9MEN1KMT2A | |
| SCHEMBL19821287 | 0.95 | BTN3A1 (0.47) | BTN3A1CYP3A4CYP2C9MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250057867-A1 | NUCLEOSIDE PHOSPHORAMIDATES | GILEAD SCIENCES INC (US) | 2025-02-20 | — | — | US | claimed |
| EP-2609923-B1 | PROCESS FOR THE CRYSTALLISATION OF (S)-ISOPROPYL 2-(((S)-(PERFLUOROPHENOXY)(PHENOXY)PHOSPHORYL)AMINO)PROPANOATE | GILEAD PHARMASSET LLC (US) | 2017-05-24 | — | — | EP | claimed |
| EP-2609923-A2 | Nucleoside Phosphoramidates | Gilead Pharmasset LLC (US) | 2013-07-03 | — | — | EP | claimed |
| EP-2552930-A2 | NUCLEOSIDE PHOSPHORAMIDATES | Gilead Pharmasset LLC (US) | 2013-02-06 | — | — | EP | claimed |
| US-20110251152-A1 | NUCLEOSIDE PHOSPHORAMIDATES | PHARMASSET, INC. (US) | 2011-10-13 | — | — | US | claimed |
| WO-2011123645-A2 | NUCLEOSIDE PHOSPHORAMIDATES | PHARMASSET, INC. (US) | 2011-10-06 | — | — | WO | claimed |
| US-20250057867-A1 | NUCLEOSIDE PHOSPHORAMIDATES | GILEAD SCIENCES INC (US) | 2025-02-20 | — | — | US | disclosed |
| EP-3290428-B1 | TABLET COMPRISING CRYSTALLINE (S)-ISOPROPYL 2-(((S)-(((2R,3R,4R,5R)-5-(2,4-DIOXO-3,4-DIHYDROPYRIMIDIN-1 (2H)-YL)-4-FLUORO-3-HYDROXY-4-METHYLTETRAHYDROFURAN-2-YL)METHOXY)(PHENOXY)PHOSPHORYL)AMINO)PROPANOATE | GILEAD PHARMASSET LLC (US) | 2021-10-13 | — | — | EP | disclosed |
| EP-3004130-B1 | 1',4'-THIO NUCLEOSIDES FOR THE TREATMENT OF HCV | IDENIX PHARMACEUTICALS LLC (US) | 2019-08-07 | — | — | EP | disclosed |
| US-10251903-B2 | Process for making nucleoside phosphoramidate compounds | MERCK SHARP & DOHME CORP. (US) | 2019-04-09 | — | — | US | disclosed |
| EP-3290428-A1 | TABLET COMPRISING CRYSTALLINE (S)-ISOPROPYL 2-(((S)-(((2R,3R,4R,5R)-5-(2,4-DIOXO-3,4-DIHYDROPYRIMIDIN-1 (2H)-YL)-4-FLUORO-3-HYDROXY-4-METHYLTETRAHYDROFURAN-2-YL)METHOXY)(PHENOXY)PHOSPHORYL)AMINO)PROPANOATE | Gilead Pharmasset LLC (US) | 2018-03-07 | — | — | EP | disclosed |
| US-20170246198-A1 | Process for Making Nucleoside Phosphoramidate Compounds | IDENIX PHARMACEUTICALS LLC (US) | 2017-08-31 | — | — | US | disclosed |
| EP-2609923-B1 | PROCESS FOR THE CRYSTALLISATION OF (S)-ISOPROPYL 2-(((S)-(PERFLUOROPHENOXY)(PHENOXY)PHOSPHORYL)AMINO)PROPANOATE | GILEAD PHARMASSET LLC (US) | 2017-05-24 | — | — | EP | disclosed |
| US-8618076-B2 | Nucleoside phosphoramidates | GILEAD PHARMASSET LLC (US) | 2013-12-31 | — | — | US | disclosed |
| US-20130310551-A1 | NUCLEOSIDE PHOSPHORAMIDATES | GILEAD SCIENCES, INC. | 2013-11-21 | — | — | US | disclosed |
| US-20130288997-A1 | NUCLEOSIDE PHOSPHORAMIDATES | GILEAD SCIENCES, INC. | 2013-10-31 | — | — | US | disclosed |
| EP-2609923-A2 | Nucleoside Phosphoramidates | Gilead Pharmasset LLC (US) | 2013-07-03 | — | — | EP | disclosed |
| EP-2552930-A2 | NUCLEOSIDE PHOSPHORAMIDATES | Gilead Pharmasset LLC (US) | 2013-02-06 | — | — | EP | disclosed |
| US-20110251152-A1 | NUCLEOSIDE PHOSPHORAMIDATES | PHARMASSET, INC. (US) | 2011-10-13 | — | — | US | disclosed |
| WO-2011123645-A2 | NUCLEOSIDE PHOSPHORAMIDATES | PHARMASSET, INC. (US) | 2011-10-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170246198-A1 | Process for Making Nucleoside Phosphoramidate Compounds | PNP, NUDT1, NUDT14 | BTN3A1 4161/4885CYP3A4 418/4885CYP2C9 308/4885 |
| US-20130310551-A1 | NUCLEOSIDE PHOSPHORAMIDATES | PNP, RNGTT, NSUN2 | BTN3A1 3601/4885CYP3A4 3916/4885CYP2C9 4098/4885 |
| US-20250057867-A1 | NUCLEOSIDE PHOSPHORAMIDATES | PNP, RNGTT, NSUN2 | BTN3A1 3601/4885CYP3A4 3916/4885CYP2C9 4098/4885 |
| US-20130288997-A1 | NUCLEOSIDE PHOSPHORAMIDATES | PNP, RNGTT, NSUN2 | BTN3A1 3601/4885CYP3A4 3916/4885CYP2C9 4098/4885 |
| US-10251903-B2 | Process for making nucleoside phosphoramidate compounds | PNP, NUDT1, NUDT14 | BTN3A1 4161/4885CYP3A4 418/4885CYP2C9 308/4885 |
| US-20110251152-A1 | NUCLEOSIDE PHOSPHORAMIDATES | PNP, RNGTT, NSUN2 | BTN3A1 3601/4885CYP3A4 3916/4885CYP2C9 4098/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.